The main role of Apolipoprotein A-I (Apo A-I) is in the removal of excess cholesterol from extra-hepatic tissues.
Like HDL Cholesterol Apo A-I can be described as non-atherogenic showing an inverse relationship to cardiovascular disease risk. Individuals with cardiovascular disease generally have reduced levels of Apo A-I and increased levels of Apo B. The Randox Apo A-I assay is based on an immunoturbidimetric method. All reagents are liquid ready-to-use and suitable for use on a wide range of chemistry analysers.